Wire · opportunities
Tozorakimab Cuts COPD Exacerbations Across Eosinophil Levels
◆ Sectors
◆ Source
◆ Verified
Fusion42 · 18 September 2026 · Fusion42 review
Tozorakimab significantly reduces exacerbations in Chronic Obstructive Pulmonary Disease (COPD) patients regardless of their eosinophil level, indicating broad efficacy across patient subgroups.
This Wire brief sits within Fusion42's coverage of Biotech and Drug Discovery, and 2 sources have reported it between 9 Sep 2026 and 17 Sep 2026.
◆ ◆ The Wire takeaway
You have a wider patient base to target with tozorakimab because it works irrespective of eosinophil levels. Expand your clinical focus to include COPD patients often excluded from eosinophil-targeted therapies.
◆ Coverage
2 sources · first reported 9 Sep 2026 · latest 17 Sep 2026
◆ Related on Wire
◆ Topics